According to population life table and survival analysis theory, the time-specific life table and the survival function curve of Alsophila spinulosa population were established and drawn based on height class, and the life process of the population was analyzed. The results revealed that the population structure of A. spinulosa was of the type ascending at early stage and stable at late stage. The peak of expected life appeared at the 4th age class, indicating the relative good survival quality at this phase, and the survival curve belonged to the typical form of Deevey-III. There existed three death peak phases in the population life process, i.e., the growth stages from 2nd to 3rd age class, from 10th to 11th age class, and from 12th to 13th age class. With the increase of age class, the population survivability dropped down monotonously, and ow nosy, a the accumulative mortality rose up correspondently. The variation extent was high in early phase and low in anaphase. The death density function curve displayed the characteristics of descent in early phase and stabilization in anaphase, and the concave point occurred at 4th age class. Spectral analysis showed that the quantitative fluctuation of A. spinulosa population was multi-harmonic superposition with large cycles containing small cycles. The influences of these cycles dropped with the diminishment of cycle length, and the effect of fundamental wave was most prominent.
Download full-text PDF |
Source |
---|
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: Faricimab is predominantlyprescribed for conditions such as age-related macular degeneration (AMD),diabetic macular edema (DME), and macular edema related to retinal veinocclusion (RVO-ME). Currently, a notable absence of large-scale, real-worldstudies focusing on the adverse reactions of faricimab exists.
Methods: Thisstudy assesses the side effects of faricimab by analyzing reports of adverseevents (AEs) from the FDA's AEReporting System (FAERS) database.
Ann Med
December 2025
Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia.
Background: Most older patients with atrial fibrillation (AF) have comorbidities. However, it is unclear whether specific comorbidity patterns are associated with adverse outcomes. We identified comorbidity patterns and their association with mortality in multimorbid older AF patients with different multidimensional frailty.
View Article and Find Full Text PDFJ Coll Physicians Surg Pak
January 2025
Department of General and Laparoscopic Surgery, Sheikh Khalifa Bin Zayed Al-Nahyan Hospital Muzaffarabad, Azad Jammu and Kashmir, Pakistan.
Objective: To determine the importance of the Glasgow Coma scale (GCS), ASA physical status classification system, and P-POSSUM score in predicting mortality among patients undergoing emergency laparotomies.
Study Design: An analytical study. Place and Duration of the Study: Department of General Surgery, Sheikh Khalifa Bin Zayed Al-Nahyan Hospital Muzaffarabad, Pakistan, from October 2020 to January 2022.
Hum Mol Genet
January 2025
Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Background: Individuals with cystic fibrosis (CF; a recessive disorder) have an increased risk of colorectal cancer (CRC). Evidence suggests individuals with a single CFTR variant may also have increased CRC risk.
Methods: Using population-based studies (GECCO, CORECT, CCFR, and ARIC; 53 785 CRC cases and 58 010 controls), we tested for an association between the most common CFTR variant (Phe508del) and CRC risk.
J Headache Pain
January 2025
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, USA.
Background: Migraine progression, particularly from episodic to chronic migraine (CM), increases disease burden and healthcare costs. Understanding the new concept of "Medication Underuse Headache" should encourage the health care provider to consider early intervention with calcitonin gene-related peptide (CGRP) monoclonal antibodies. Galcanezumab given early in the course of the disease, may prevent migraine chronification and have a robust response, moreso than when initiated in later stages of migraine.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!